Virax Biolabs
VRAX
5 hedge funds and large institutions have $1.14M invested in Virax Biolabs in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.
15% more capital invested
Capital invested by funds: $990K → $1.14M (+$150K)
0.04% more ownership
Funds ownership: 0.01% → 0.05% (+0.04%)
29% less funds holding
Funds holding: 7 → 5 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.17M |
| 2 |
TSS
Two Sigma Securities
New York
|
+$19.2K |
| 3 |
HF
HRT Financial
New York
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
-$858K |
| 2 |
VF
Virtu Financial
New York
|
-$35K |
| 3 |
Millennium Management
New York
|
-$11K |
| 4 |
Renaissance Technologies
New York
|
-$8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $1.04M | +$1.17M | +6,000 | New |
|
2
Legal & General Group
London,
United Kingdom
| $68.4K | -$2.14K | -11 | -3% |
|
|
TSS
3
Two Sigma Securities
New York
| $17.2K | +$19.2K | +99 | New |
|
|
HF
4
HRT Financial
New York
| $10K | +$12K | +62 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $2.13K | -$2.53K | -13 | -52% |
|
|
KI
6
Kapitalo Investimentos
Sao Paulo,
Brazil
| – | -$858K | -470 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$35K | -194 | Closed |
|
|
8
Millennium Management
New York
| – | -$11K | -62 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$8K | -46 | Closed |
|
10
Morgan Stanley
New York
| – | -$623 | -3 | Closed |
|
|
RAM
11
Riggs Asset Management
Dallas,
Pennsylvania
| – | -$3 | – | – |
|
VRAX Hedge Fund Activity: Q1 2023 in Review
5 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q1 2023, worth a combined $1.14M — up 15% from $990K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VRAX and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.17M. The largest seller was Kapitalo Investimentos, exiting entirely with an estimated $858K sold.
- 5 institutional investors held Virax Biolabs (VRAX) as of Q1 2023, down from 7 in Q4 2022.
- Funds reported $1.14M of Virax Biolabs stock for Q1 2023, up 15% quarter-over-quarter.
- 3 funds opened new Virax Biolabs positions in Q1 2023 and 5 closed out, a net change of -2 holders.
- The largest Virax Biolabs buyer in Q1 2023 was Armistice Capital, an estimated $1.17M added.
- The largest Virax Biolabs seller in Q1 2023 was Kapitalo Investimentos, an estimated $858K sold.
Based on aggregated 13F filings for Q1 2023.